Search
for
Did you mean JAK1/2 inhibitor?
Sort by
Research 30 of 774
- JAK inhibitors in dermatology: The promise of a new drug class
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Under Development JAK Inhibitors for Dermatologic Diseases
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- JAK Inhibitors for Treatment of Alopecia Areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Janus kinase inhibitors for alopecia areata: A narrative review
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Janus Kinase inhibitors in dermatology: a review
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review